Cord blood cells join forces with targeted drug to hunt down hidden colon cancer
NCT ID NCT05040568
First seen Jan 28, 2026 · Last updated May 11, 2026 · Updated 10 times
Summary
This early-phase study tested a new immunotherapy approach in 15 colon cancer patients who had completed standard treatments but still had tiny traces of cancer DNA in their blood (minimal residual disease). The treatment combined specially activated cord blood natural killer (CB-NK) cells with the targeted drug cetuximab. The goal was to see if this combination could eliminate those remaining cancer cells and prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.